Methods for reducing cardiovascular risk

A method for reducing the risk of coronary heart disease (CHD) death, non-fatal myocardial infarction, unstable angina requiring hospitalization, or ischemic stroke comprising:

• administering to a patient in need thereof a therapeutically effective amount of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen-binding fragment thereof, wherein the PCSK9 antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising amino acid sequences set forth in SEQ ID NOs:
• 1 and 6, respectively;
• and
• wherein the patient is a high cardiovascular risk patient.

A method for reducing the risk of a coronary heart disease (CHD) event, comprising:

• (b) administering to a patient in need thereof a therapeutically effective amount of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen-binding fragment thereof, wherein the PCSK9 antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) and a light chain variable region (LCVR) comprising amino acid sequences set forth in SEQ ID NOs:
• 1 and 6, respectively;
• and
• wherein the patient is a high cardiovascular risk patient.

A method for reducing the risk of a cardiovascular event comprising:

• administering to a patient in need thereof a therapeutically effective amount of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen-binding fragment thereof, wherein the PCSK9 antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) add a light chain variable region (LCVR) comprising amino acid sequences set forth in SEQ ID NOs:
• 1 and 6, respectively;
• and
• wherein the patient is a high cardiovascular risk patient.